European Consortium for Waldenström's Macroglobulinemia
Epcoritamab is being evaluated in a prospective phase I/II trial for relapsed or refractory Waldenstrom’s macroglobulinemia.
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia
- Waldenstrom's Macroglobulinemia Clinical Trials and Research | Dana‑Farber Cancer Institute